U-104 is primarily researched for its potential therapeutic applications, particularly in the field of oncology. It has shown promise as a selective inhibitor of carbonic anhydrase IX (CA IX), an enzyme that is overexpressed in many types of cancer cells. By inhibiting CA IX, U-104 can disrupt the pH regulation within tumor cells, making the tumor microenvironment less conducive to cancer growth and survival. This mechanism makes it a candidate for targeted cancer therapy, especially in hypoxic tumors where CA IX activity is elevated. Additionally, its selectivity for CA IX over other carbonic anhydrase isoforms reduces the risk of off-target effects, enhancing its potential as a safe and effective treatment option. Ongoing studies are exploring its efficacy in combination with other anticancer agents to improve therapeutic outcomes.